ATLANTA and PHILADELPHIA, June 26 /PRNewswire-FirstCall/ --
-- GSK's ROTARIX(R) [Rotavirus Vaccine, Live, Oral] recommended for routine vaccination of infants to protect against rotavirus gastroenteritis (RGE)
-- ROTARIX, approved by the FDA on April 3, 2008, is the only rotavirus vaccine that offers completion of rotavirus immunization by four months of age in just two oral doses
-- GSK's KINRIX(TM) [Diphtheria and Tetanus Toxoids and Acellular Pertussis Adsorbed and Inactivated Poliovirus Vaccine] recommended for vaccination of children to protect against diphtheria, tetanus, pertussis and polio diseases
-- KINRIX was approved by the FDA on June 24, 2008 to offer protection against four serious diseases (diphtheria, tetanus, pertussis and polio) in one shot for eligible 4 to 6 year-olds
GlaxoSmithKline (NYSE: GSK) announced today that the U.S. Centers for Disease Control and Prevention's (CDC's) Advisory Committee on Immunization Practices (ACIP) voted to include the company's two newest pediatric vaccines, ROTARIX(R) [Rotavirus Vaccine, Live, Oral] and KINRIX(TM) [Diphtheria and Tetanus Toxoids and Acellular Pertussis Adsorbed and Inactivated Poliovirus Vaccine], in the childhood immunization program. ROTARIX is a two-dose oral rotavirus vaccine for infants and KINRIX is a combination vaccine that protects children against four diseases (diphtheria, tetanus, pertussis and polio) in one shot. These vaccines are additions to GSK's expanding U.S. vaccines portfolio, which includes some of the most widely used immunizations for serious vaccine-preventable diseases in infants, adolescents and adults.
"The advisory committee's recommendations for ROTARIX and KINRIX are
Copyright©2008 PR Newswire.
All rights reserved